Published in FEMS Microbiol Rev on July 09, 2008
Trial of Two Strains of BCG (BCGSTRAIN) | NCT02447536
Trial to Compare Two Strains of BCG (STRAIN III) | NCT04383925
BCG Vaccination to Prevent COVID-19 (NUEVA) | NCT04632537
Prevention of Acute Respiratory Infection in Taiwanese Institutionalized Elderly | NCT04938323
BCG immunotherapy for bladder cancer--the effects of substrain differences. Nat Rev Urol (2013) 1.60
In vivo biosynthesis of terpene nucleosides provides unique chemical markers of Mycobacterium tuberculosis infection. Chem Biol (2015) 1.41
Latent tuberculosis: what the host "sees"? Immunol Res (2011) 1.35
Susceptibility of Mycobacterium bovis BCG vaccine strains to antituberculous antibiotics. Antimicrob Agents Chemother (2008) 1.29
Tuberculosis vaccines in clinical trials. Expert Rev Vaccines (2011) 1.26
Perspectives on clinical and preclinical testing of new tuberculosis vaccines. Clin Microbiol Rev (2010) 1.13
The influence of BCG vaccine strain on mycobacteria-specific and non-specific immune responses in a prospective cohort of infants in Uganda. Vaccine (2012) 1.08
Impact of in vitro evolution on antigenic diversity of Mycobacterium bovis bacillus Calmette-Guerin (BCG). Vaccine (2014) 0.99
Mycobacterium microti: More diverse than previously thought. J Clin Microbiol (2009) 0.95
The role of biomedical research in global tuberculosis control: gaps and challenges: A perspective from the US National Institute of Allergy and Infectious Diseases, National Institutes of Health. Emerg Microbes Infect (2012) 0.89
The impact of transcriptomics on the fight against tuberculosis: focus on biomarkers, BCG vaccination, and immunotherapy. Clin Dev Immunol (2010) 0.88
The role of environmental factors in modulating immune responses in early life. Front Immunol (2014) 0.88
Effectiveness of routine BCG vaccination on buruli ulcer disease: a case-control study in the Democratic Republic of Congo, Ghana and Togo. PLoS Negl Trop Dis (2015) 0.84
A side-by-side comparison of T cell reactivity to fifty-nine Mycobacterium tuberculosis antigens in diverse populations from five continents. Tuberculosis (Edinb) (2015) 0.83
Variable Virulence and Efficacy of BCG Vaccine Strains in Mice and Correlation With Genome Polymorphisms. Mol Ther (2015) 0.83
Prospects in Mycobacterium bovis Bacille Calmette et Guérin (BCG) vaccine diversity and delivery: why does BCG fail to protect against tuberculosis? Vaccine (2015) 0.82
Nonclinical Development of BCG Replacement Vaccine Candidates. Vaccines (Basel) (2013) 0.81
Molecular confirmation of Bacillus Calmette Guerin vaccine related adverse events among Saudi Arabian children. PLoS One (2014) 0.81
Increasing the Vaccine Potential of Live M. bovis BCG by Coadministration with Plasmid DNA Encoding a Tuberculosis Prototype Antigen. Vaccines (Basel) (2014) 0.80
Severe osteomyelitis as a complication of Tokyo-172 BCG vaccination. J Korean Med Sci (2012) 0.79
Complete Genome Sequence of Mycobacterium bovis Strain BCG-1 (Russia). Genome Announc (2016) 0.78
The BCG Strain Pool: Diversity Matters. Mol Ther (2016) 0.77
Editorial Commentary: Different Strains of Bacillus Calmette-Guérin Vaccine Have Very Different Effects on Tuberculosis and on Unrelated Infections. Clin Infect Dis (2015) 0.77
Lack of a Negative Effect of BCG-Vaccination on Child Psychomotor Development: Results from the Danish Calmette Study - A Randomised Clinical Trial. PLoS One (2016) 0.75
The Adverse Events, Signs, and Management of Neonatal Bacillus Calmette-Guérin Vaccine Overdose. Oman Med J (2016) 0.75
Influence of advanced age on Mycobacterium bovis BCG vaccination in guinea pigs aerogenically infected with Mycobacterium tuberculosis. Clin Vaccine Immunol (2010) 0.75
Why don't we have an effective tuberculosis vaccine yet? Expert Rev Vaccines (2016) 0.75
Commonly administered bacille Calmette-Guerin strains induce comparable immune response. Int J Clin Exp Med (2015) 0.75
Minimal Sex-Differential Modulation of Reactivity to Pathogens and Toll-Like Receptor Ligands following Infant Bacillus Calmette-Guérin Russia Vaccination. Front Immunol (2017) 0.75
The Recombinant Bacille Calmette-Guérin Vaccine VPM1002: Ready for Clinical Efficacy Testing. Front Immunol (2017) 0.75
Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial. Lancet (2013) 8.18
TNF regulates chemokine induction essential for cell recruitment, granuloma formation, and clearance of mycobacterial infection. J Immunol (2002) 3.96
Distinct, specific IL-17- and IL-22-producing CD4+ T cell subsets contribute to the human anti-mycobacterial immune response. J Immunol (2008) 3.19
Contact investigation for tuberculosis: a systematic review and meta-analysis. Eur Respir J (2012) 2.99
Dominant TNF-α+ Mycobacterium tuberculosis-specific CD4+ T cell responses discriminate between latent infection and active disease. Nat Med (2011) 2.77
Specific T cell frequency and cytokine expression profile do not correlate with protection against tuberculosis after bacillus Calmette-Guérin vaccination of newborns. Am J Respir Crit Care Med (2010) 2.64
Epidemiology, etiology, pathogenesis, and diagnosis of recurrent bacterial meningitis. Clin Microbiol Rev (2008) 2.57
Sick and tired: Does sleep have a vital role in the immune system? Nat Rev Immunol (2004) 2.52
The influence of bacille Calmette-Guerin vaccine strain on the immune response against tuberculosis: a randomized trial. Am J Respir Crit Care Med (2011) 2.48
Life and death in the granuloma: immunopathology of tuberculosis. Immunol Cell Biol (2007) 2.46
Bacillus Calmette-Guérin vaccination of human newborns induces T cells with complex cytokine and phenotypic profiles. J Immunol (2008) 2.27
Modified vaccinia Ankara-expressing Ag85A, a novel tuberculosis vaccine, is safe in adolescents and children, and induces polyfunctional CD4+ T cells. Eur J Immunol (2010) 2.25
Dose-finding study of the novel tuberculosis vaccine, MVA85A, in healthy BCG-vaccinated infants. J Infect Dis (2011) 2.24
Evolution of multidrug resistance during Staphylococcus aureus infection involves mutation of the essential two component regulator WalKR. PLoS Pathog (2011) 2.15
Functional capacity of Mycobacterium tuberculosis-specific T cell responses in humans is associated with mycobacterial load. J Immunol (2011) 2.07
Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in healthy adults in South Africa. J Infect Dis (2008) 2.05
The novel tuberculosis vaccine, AERAS-402, induces robust and polyfunctional CD4+ and CD8+ T cells in adults. Am J Respir Crit Care Med (2010) 2.03
Infants born in Australia to mothers from countries with a high prevalence of tuberculosis: to BCG or not to BCG? Med J Aust (2013) 1.96
Epstein-Barr nuclear antigen 1-specific CD4(+) Th1 cells kill Burkitt's lymphoma cells. J Immunol (2002) 1.92
Immunological outcomes of new tuberculosis vaccine trials: WHO panel recommendations. PLoS Med (2008) 1.91
Antigen load governs the differential priming of CD8 T cells in response to the bacille Calmette Guerin vaccine or Mycobacterium tuberculosis infection. J Immunol (2009) 1.90
Chips with everything: DNA microarrays in infectious diseases. Lancet Infect Dis (2004) 1.87
Evidence on the use of paracetamol in febrile children. Bull World Health Organ (2003) 1.87
Risk factors for intussusception in infants in Vietnam and Australia: adenovirus implicated, but not rotavirus. J Pediatr (2006) 1.84
Human MAIT and CD8αα cells develop from a pool of type-17 precommitted CD8+ T cells. Blood (2011) 1.83
Tuberculin skin test and in vitro assays provide complementary measures of antimycobacterial immunity in children and adolescents. Chest (2009) 1.68
The effect of bacille Calmette-Guérin vaccine strain and route of administration on induced immune responses in vaccinated infants. J Infect Dis (2006) 1.64
A polymorphism in the P2X7 gene increases susceptibility to extrapulmonary tuberculosis. Am J Respir Crit Care Med (2006) 1.63
How reliable is a negative blood culture result? Volume of blood submitted for culture in routine practice in a children's hospital. Pediatrics (2007) 1.63
Autocrine IL-10 impairs dendritic cell (DC)-derived immune responses to mycobacterial infection by suppressing DC trafficking to draining lymph nodes and local IL-12 production. Eur J Immunol (2002) 1.59
Formal infectious diseases consultations at a tertiary pediatric hospital: a 14-year review. Pediatr Infect Dis J (2014) 1.54
HIV-1 infection impairs the bronchoalveolar T-cell response to mycobacteria. Am J Respir Crit Care Med (2009) 1.54
A three-way comparison of tuberculin skin testing, QuantiFERON-TB gold and T-SPOT.TB in children. PLoS One (2008) 1.53
Ureaplasma: pathogen or passenger in neonatal meningitis? Pediatr Infect Dis J (2010) 1.52
Update on Kawasaki disease: epidemiology, aetiology and pathogenesis. J Paediatr Child Health (2013) 1.49
A Thr357 to Ser polymorphism in homozygous and compound heterozygous subjects causes absent or reduced P2X7 function and impairs ATP-induced mycobacterial killing by macrophages. J Biol Chem (2005) 1.47
Antibiotic treatment for bacterial meningitis in children in developing countries. Ann Trop Paediatr (2003) 1.45
Delaying BCG vaccination from birth to 10 weeks of age may result in an enhanced memory CD4 T cell response. Vaccine (2009) 1.45
Transmembrane TNF is sufficient to initiate cell migration and granuloma formation and provide acute, but not long-term, control of Mycobacterium tuberculosis infection. J Immunol (2005) 1.44
Enterovirus infections in neonates. Semin Fetal Neonatal Med (2009) 1.42
The tuberculin skin test versus QuantiFERON TB Gold® in predicting tuberculosis disease in an adolescent cohort study in South Africa. PLoS One (2011) 1.42
Bacillus Calmette Guerin vaccination of human newborns induces a specific, functional CD8+ T cell response. J Immunol (2006) 1.40
A new recombinant bacille Calmette-Guérin vaccine safely induces significantly enhanced tuberculosis-specific immunity in human volunteers. J Infect Dis (2008) 1.39
Two loci control tuberculin skin test reactivity in an area hyperendemic for tuberculosis. J Exp Med (2009) 1.38
A loss-of-function polymorphism in the human P2X7 receptor abolishes ATP-mediated killing of mycobacteria. J Immunol (2003) 1.36
Novel application of Ki67 to quantify antigen-specific in vitro lymphoproliferation. J Immunol Methods (2010) 1.35
Invasive group a streptococcal disease: epidemiology, pathogenesis and management. Drugs (2012) 1.35
Lymphocyte recruitment and protective efficacy against pulmonary mycobacterial infection are independent of the route of prior Mycobacterium bovis BCG immunization. Infect Immun (2002) 1.34
Mycobacterium bovis BCG-specific Th17 cells confer partial protection against Mycobacterium tuberculosis infection in the absence of gamma interferon. Infect Immun (2010) 1.34
QuantiFERON-TB Gold: state of the art for the diagnosis of tuberculosis infection? Expert Rev Mol Diagn (2006) 1.33
Induction and regulation of T-cell immunity by the novel tuberculosis vaccine M72/AS01 in South African adults. Am J Respir Crit Care Med (2013) 1.31
Interleukin-23 restores immunity to Mycobacterium tuberculosis infection in IL-12p40-deficient mice and is not required for the development of IL-17-secreting T cell responses. J Immunol (2006) 1.31
Susceptibility of Mycobacterium bovis BCG vaccine strains to antituberculous antibiotics. Antimicrob Agents Chemother (2008) 1.29
Fatal case of toxic shock-like syndrome due to group C streptococcus associated with superantigen exotoxin. J Clin Microbiol (2004) 1.29
T cells and adaptive immunity to Mycobacterium tuberculosis in humans. Immunol Rev (2015) 1.26
Comparison of T-SPOT.TB assay and tuberculin skin test for the evaluation of young children at high risk for tuberculosis in a community setting. Pediatrics (2009) 1.23
A comparison of IFNgamma detection methods used in tuberculosis vaccine trials. Tuberculosis (Edinb) (2008) 1.21
Targeting dendritic cells with antigen-containing liposomes: a highly effective procedure for induction of antitumor immunity and for tumor immunotherapy. Cancer Res (2004) 1.21
High heritability of antimycobacterial immunity in an area of hyperendemicity for tuberculosis disease. J Infect Dis (2010) 1.21
Longitudinal changes in CD4(+) T-cell memory responses induced by BCG vaccination of newborns. J Infect Dis (2013) 1.17
Distribution of tccP in clinical enterohemorrhagic and enteropathogenic Escherichia coli isolates. J Clin Microbiol (2005) 1.17
The Mycobacterium tuberculosis cysD and cysNC genes form a stress-induced operon that encodes a tri-functional sulfate-activating complex. Microbiology (2004) 1.15
Strain prevalence, rather than innate virulence potential, is the major factor responsible for an increase in serious group A streptococcus infections. J Infect Dis (2007) 1.14
Vaccines, global health and social equity. Immunol Cell Biol (2009) 1.14
Plasmid interleukin-23 (IL-23), but not plasmid IL-27, enhances the protective efficacy of a DNA vaccine against Mycobacterium tuberculosis infection. Infect Immun (2006) 1.14
Some of the people, some of the time: susceptibility to acute rheumatic fever. Circulation (2009) 1.14
Association of human TLR1 and TLR6 deficiency with altered immune responses to BCG vaccination in South African infants. PLoS Pathog (2011) 1.13
Genetic susceptibility to mycobacterial disease in humans. Immunol Cell Biol (2006) 1.13
Thalidomide and a thalidomide analogue drug costimulate virus-specific CD8+ T cells in vitro. J Infect Dis (2003) 1.13
HIV-1 infection in infants severely impairs the immune response induced by Bacille Calmette-Guérin vaccine. J Infect Dis (2009) 1.12
Eighteen-month outcomes of house dust mite avoidance and dietary fatty acid modification in the Childhood Asthma Prevention Study (CAPS). J Allergy Clin Immunol (2003) 1.12
A whole blood assay to assess peripheral blood dendritic cell function in response to Toll-like receptor stimulation. J Immunol Methods (2006) 1.12
Burden of acute sore throat and group A streptococcal pharyngitis in school-aged children and their families in Australia. Pediatrics (2007) 1.11
Dissection of regenerating T-Cell responses against tuberculosis in HIV-infected adults sensitized by Mycobacterium tuberculosis. Am J Respir Crit Care Med (2009) 1.09
TccP2 of O157:H7 and non-O157 enterohemorrhagic Escherichia coli (EHEC): challenging the dogma of EHEC-induced actin polymerization. Infect Immun (2006) 1.09
A phase IIa trial of the new tuberculosis vaccine, MVA85A, in HIV- and/or Mycobacterium tuberculosis-infected adults. Am J Respir Crit Care Med (2012) 1.09
Interferon-γ release assays for the diagnosis of tuberculosis in children. Arch Dis Child (2012) 1.08
Predominance of interleukin-22 over interleukin-17 at the site of disease in human tuberculosis. Tuberculosis (Edinb) (2011) 1.08
The dynamics of QuantiFERON-TB gold in-tube conversion and reversion in a cohort of South African adolescents. Am J Respir Crit Care Med (2015) 1.08
The "surreptitious Staphylococcus": Staphylococcus lugdunensis endocarditis in a child. Pediatr Infect Dis J (2002) 1.07
Cutinase-like proteins of Mycobacterium tuberculosis: characterization of their variable enzymatic functions and active site identification. FASEB J (2009) 1.07
Early detection of perinatal tuberculosis using a whole blood interferon-gamma release assay. Clin Infect Dis (2006) 1.07
Mycobacterium tuberculosis peptides presented by HLA-E molecules are targets for human CD8 T-cells with cytotoxic as well as regulatory activity. PLoS Pathog (2010) 1.06
Non-typhoidal Salmonella in children: microbiology, epidemiology and treatment. Adv Exp Med Biol (2013) 1.06
Superantigen genes in group A streptococcal isolates and their relationship with emm types. J Med Microbiol (2008) 1.05
Inflammatory responses to individual microorganisms in the lungs of children with cystic fibrosis. Clin Infect Dis (2011) 1.05
A strategy to determine HLA class II restriction broadly covering the DR, DP, and DQ allelic variants most commonly expressed in the general population. Immunogenetics (2013) 1.04
Single chain antibody fragments for the selective targeting of antigens to dendritic cells. Mol Immunol (2004) 1.04
Mapping the global use of different BCG vaccine strains. Tuberculosis (Edinb) (2009) 1.04
CD4 and CD8 T-cell responses to mycobacterial antigens in African children. Am J Respir Crit Care Med (2010) 1.04
Higher human CD4 T cell response to novel Mycobacterium tuberculosis latency associated antigens Rv2660 and Rv2659 in latent infection compared with tuberculosis disease. Vaccine (2010) 1.03
An update on Kawasaki disease II: clinical features, diagnosis, treatment and outcomes. J Paediatr Child Health (2013) 1.02